Navigation Links
IGFBP-3 ELISA Test

ProductsIGFBP-3 ELISA Test
Company Diagnostic Systems Laboratories, Inc.
Item IGFBP-3 ELISA Test
Features 
Description Human Insulin-like growth factor binding protein-3 (IGFBP-3) is the main binding protein for IGF-I and IGF-II in postnatal serum, as a component of the ~150 kDa ternary complex. This complex consists of IGFBP-3, a molecule of IGF-I or IGF-II and ALS, allowing IGFBP-3, along with ALS, to regulate the actions of the IGFs. The molar concentration of IGFBP-3 in normal serum is proportional to the molar concentration of total IGFs (i.e. IGF-I + IGF-II) [1]. In addition, total IGF levels show higher correlation with GH in circulation than either IGF-I or IGF-II levels alone [2]. IGFBP-3 is GH-dependent, however IGFBP-3 may be less age-dependent than IGF-I [3]. These aspects of IGFBP-3 physiology allow its measurement to reflect GH activity. Thus, in GH deficiency of either pituitary or hypothalamic origin, IGFBP-3 levels are uniformly low. Blum et al. [3] reported that 128/132 children with GH deficiency had serum IGFBP-3 concentrations below the 5th percentile for age. In situations of GH receptor deficiency, such as Laron syndrome, anti-GH antibodies, liver disease or malnutrition, IGFBP-3 levels are also reduced, even in the presence of elevated serum GH concentrations [4]. Measurement of IGFBP-3 levels in serum is a useful diagnostic test for the clinical evaluation of GH-related disorders.

  1. Baxter R & Martin J. J Clin Invest 78:1504-12, 1986.
  2. Powell DR, et al. J Clin Endocrinol Metab 63:1186-1192, 1986.
  3. Blum WF, et al. J Clin Endocrinol Metab 70:1292-8, 1990.
  4. Guevara-Aguirre J, et al. J Clin Endocrinol Metab 76: 417-423, 1993.
Info Diagnostic Systems Laboratories, Inc.
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com

Related medicine products :

1. IMMULITE/IMMULITE 1000 IGFBP-3
2. IMMULITE 2000 IGFBP-3
3. IGFBP-3
4. IGFBP-3 IRMA Test
5. Microplate ELISA Washers - Manual Microplate Washer
6. Microplate ELISA Washers - Automated Microplate Washer
7. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
8. RELISA ANA Screening System
9. BioCheck hCG ELISA
10. Human Chorionic Gonadotropin (HCG) ELISA Kit
11. Human PSA ELISA Kit
Other Medicine News:Health News:New upper limit defined for normal ALT in adolescent males 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2008 Out-of-Pocket Drug Costs 3Health News:Former Texas Assistant Attorney General Pat O'Connell Joins Baron & Budd, P.C., to Lead Whistleblower Litigation Practice 2Health News:American Imaging Management Enters into Agreement with Scott & White Health Plan 2Health News:Regence Partners with Multnomah Education Service District to Bring Free Health Services to more than 20,000 Students in Need 2Health News:Regence Partners with Multnomah Education Service District to Bring Free Health Services to more than 20,000 Students in Need 3Health News:UCSF Medical Center using newest high-tech tool for brain disorders 2
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4